2,4-Dimethoxy-5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyrimidine, 95.0%, 5g

4,7-Dibromobenzo[c][1,2,5]oxadiazole, 95.0%, 1g

3-Iodobiphenyl, 97.0%, 10g

2-Amino-4-(2-fluorophenylamino)-1,3,5-triazine, 97.0%, 5g

6-Bromo-1,1,4,4,7-pentamethyl-1,2,3,4-tetrahydro-naphthalene, 95.0%, 500g

H-lle-OAll.TosOH, 95+%, 25g

1-(1-Methyl-1H-pyrazol-4-yl)ethanol, 95.0%, 10g

Dipropyl 2,5-Pyridinedicarboxylate>98.0%(GC)25g

bScope BS.1153-PLPHi for phase contrast. Triocular with HWF 10x/20 mm eyepieces and quintuple revolver E-plan Phase IOS 10/20/S40 S100x

(Z)-Hexadec-11-enal, 95.0%, 10g

(2R,3R,4R,5S,6S)-2-(acetoxymethyl)-6-(4-chloro-3-(4-(((S)-tetrahydrofuran-3-yl)oxy)benzyl)phenyl)tetrahydro-2H-pyran-3,4,5-triyl triacetate, 98%, 100g

Ethyl 4-acetylbenzoate, 95.0%, 5g

(R)-N-(2-Acetyl-5,8-dimethoxy-1,2,3,4-tetrahydronaphthalen-2-yl)acetamide, 98%, 1g